Skip to main content
Premium Trial:

Request an Annual Quote

Abbott s Pending Acquisition of Vysis Clears Antitrust Hurdles

NEW YORK, Nov. 23 - Abbott Laboratories' $355 million acquisition of Vysis came one step closer to closing on Friday as the Hart-Scott- Rodino Antitrust Improvements Act waiting period expired.


One month ago, Vysis agreed to be acquired by Abbott, which commenced a cash tender offer on Oct. 31 for all outstanding shares of the genomics-based disease management company for $30.50 per share, which represented a 33 percent premium. The tender offer is scheduled to expire on Nov. 29 but might have been stifled if the expiration period was extended.


Abbott, based in Abbott Park, Ill., set its sights on Vysis in the hopes of bolstering its position in the $800 million annual molecular diagnostics market.


Vysis is based in Downers Grove, Ill. It was not immediately clear when the companies hope to close the deal.

The Scan

Removal Inquiry

The Wall Street Journal reports that US lawmakers are seeking additional information about the request to remove SARS-CoV-2 sequence data from a database run by the National Institutes of Health.

Likely to End in Spring

Free lateral flow testing for SARS-CoV-2 may end in the UK by next spring, the head of Innova Medical Group says, according to the Financial Times.

Searching for More Codes

NPR reports that the US Department of Justice has accused an insurance and a data mining company of fraud.

Genome Biology Papers on GWAS Fine-Mapping Method, COVID-19 Susceptibility, Rheumatoid Arthritis

In Genome Biology this week: integrative fine-mapping approach, analysis of locus linked to COVID-19 susceptibility and severity, and more.